BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention? Expert Review of Clinical Immunology 2020;16:479-92. [DOI: 10.1080/1744666x.2020.1754194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Papp KA, Melosky B, Sehdev S, Hotte SJ, Beecker JR, Kirchhof MG, Turchin I, Dutz JP, Gooderham MJ, Gniadecki R, Hong CH, Lambert J, Lynde CW, Prajapati VH, Vender RB. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb) 2023. [PMID: 36929121 DOI: 10.1007/s13555-023-00905-3] [Reference Citation Analysis]
2 Hedderson MM, Asgari MM, Xu F, Quesenberry CP, Sridhar S, Geier J, Lemeshow AR. Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study. BMJ Open 2023;13:e071172. [PMID: 36898743 DOI: 10.1136/bmjopen-2022-071172] [Reference Citation Analysis]
3 Wang X, Wang X, Wang H, Yang M, Dong W, Shao D. Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses. BMC Pulm Med 2023;23:4. [PMID: 36604675 DOI: 10.1186/s12890-022-02297-0] [Reference Citation Analysis]
4 Zhang Y, Xu X, Cheng H, Zhou F. AIM2 and Psoriasis. Front Immunol 2023;14:1085448. [PMID: 36742336 DOI: 10.3389/fimmu.2023.1085448] [Reference Citation Analysis]
5 Rusiñol L, Camiña-Conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opin Biol Ther 2022;22:1567-78. [PMID: 36422998 DOI: 10.1080/14712598.2022.2152322] [Reference Citation Analysis]
6 Verdelli A, Caproni M, Coi A, Corrà A, Degl'Innocenti D, Vasarri M, Quintarelli L, Volpi V, Cipollini EM, Barletta E. Neutrophil Gelatinase-Associated Lipocalin as Potential Predictive Biomarker of Melanoma and Non-Melanoma Skin Cancers in Psoriatic Patients: A Pilot Study. Int J Mol Sci 2022;23. [PMID: 36293148 DOI: 10.3390/ijms232012291] [Reference Citation Analysis]
7 Kim SY, Yoo DM, Chung J, Choi HG. Thyroid Cancer and Psoriasis: A Nested Case-Control Study. Diagnostics (Basel) 2022;12. [PMID: 36291985 DOI: 10.3390/diagnostics12102297] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xu J, Li J. Construction of a three commitment points for S phase entry cell cycle model and immune-related ceRNA network to explore novel therapeutic options for psoriasis. Math Biosci Eng 2022;19:13483-525. [PMID: 36654055 DOI: 10.3934/mbe.2022630] [Reference Citation Analysis]
9 Luo Q, Chen J, Qin L, Luo Y, Zhang Y, Yang X, Wang H. Psoriasis may increase the risk of lung cancer: a two-sample Mendelian randomization study. J Eur Acad Dermatol Venereol 2022. [PMID: 35844064 DOI: 10.1111/jdv.18437] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wang J, Yang J, Cao M, Zhao Z, Cao B, Yu S. The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions. Curr Res Pharmacol Drug Discov 2021;2:100028. [PMID: 34909662 DOI: 10.1016/j.crphar.2021.100028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Butrón-Bris B, Daudén E, Rodríguez-Jiménez P. Psoriasis Therapy and Skin Cancer: A Review. Life (Basel) 2021;11:1109. [PMID: 34685480 DOI: 10.3390/life11101109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]